Iwagami Masao, Mansfield Kathryn E, Hayes Joseph F, Walters Kate, Osborn David Pj, Smeeth Liam, Nitsch Dorothea, Tomlinson Laurie A
Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.
Division of Psychiatry, University College London, London, UK.
Clin Epidemiol. 2018 Apr 16;10:421-429. doi: 10.2147/CLEP.S154841. eCollection 2018.
We investigated the burden of chronic kidney disease (CKD) among patients with severe mental illness (SMI).
We identified patients with SMI among all those aged 25-74 registered in the UK Clinical Practice Research Datalink as on March 31, 2014. We compared the prevalence of CKD (two measurements of estimated glomerular filtration rate <60 mL/min/1.73 m for ≥3 months) and renal replacement therapy between patients with and without SMI. For patients with and without a history of lithium prescription separately, we used logistic regression to examine the association between SMI and CKD, adjusting for demographics, lifestyle characteristics, and known CKD risk factors.
The CKD prevalence was 14.6% among patients with SMI and a history of lithium prescription (n = 4,295), 3.3% among patients with SMI and no history of lithium prescription (n = 24,101), and 2.1% among patients without SMI (n = 2,387,988; < 0.001). The prevalence of renal replacement therapy was 0.23%, 0.15%, and 0.11%, respectively ( = 0.012). Compared to patients without SMI, the fully adjusted odds ratio for CKD was 6.49 (95% CI 5.84-7.21) for patients with SMI and a history of lithium prescription and 1.45 (95% CI 1.34-1.58) for patients with SMI and no history of lithium prescription. The higher prevalence of CKD in patients with SMI may, in part, be explained by more frequent blood testing as compared to the general population.
CKD is identified more commonly among patients with SMI than in the general population.
我们调查了重症精神疾病(SMI)患者中慢性肾脏病(CKD)的负担。
我们在英国临床实践研究数据链中登记的所有25至74岁患者中,确定了截至2014年3月31日患有SMI的患者。我们比较了患有和未患有SMI的患者之间CKD的患病率(估算肾小球滤过率两次测量值<60 mL/min/1.73 m²且持续≥3个月)以及肾脏替代治疗情况。对于分别有和无锂盐处方史的患者,我们使用逻辑回归分析来检验SMI与CKD之间的关联,并对人口统计学、生活方式特征和已知的CKD危险因素进行了调整。
有锂盐处方史的SMI患者中CKD患病率为14.6%(n = 4295),无锂盐处方史的SMI患者中为3.3%(n = 24101),无SMI的患者中为2.1%(n = 2387988;P < 0.001)。肾脏替代治疗的患病率分别为0.23%、0.15%和0.11%(P = 0.012)。与无SMI的患者相比,有锂盐处方史的SMI患者CKD的完全调整优势比为6.49(95%可信区间5.84 - 7.21),无锂盐处方史的SMI患者为1.45(95%可信区间1.34 - 1.58)。与普通人群相比,SMI患者中CKD患病率较高,部分原因可能是与普通人群相比,他们接受血液检测更为频繁。
与普通人群相比,SMI患者中CKD的确诊更为常见。